He's estimating the pharmacy conglomerate will post a non-GAAP (adjusted) net profit of $1.71 per share for fiscal 2025, which is well below the $2.85 consensus pundit forecast for this year. Yet ...
According to reports, Loop Capital analyst Laura Champine just upgraded the stock from a "hold" to a "buy" and raised her firm's price target from $360 to $460 per share. That price would represent ...